Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - Commentary

Peter A. Calabresi; Peter C.M. Van Zijl

doi:10.1177/1352458516684560

Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - Commentary

Peter A. Calabresi, Peter C.M. Van Zijl

School of Medicine

Research output: Contribution to journal › Short survey › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	376-377
Number of pages	2
Journal	Multiple Sclerosis
Volume	23
Issue number	3
DOIs	https://doi.org/10.1177/1352458516684560
State	Published - Mar 1 2017

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1177/1352458516684560

Cite this

@article{8e584d59f97944ad80a7d6c196772f25,

title = "Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - Commentary",

author = "Calabresi, {Peter A.} and {Van Zijl}, {Peter C.M.}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: P.A.C. has received grant support from MedImmune, Biogen, Teva and Novartis and has received consulting fees from Biogen and Vertex. P.C.M.V.Z has received grant support from NIH P41EB015909.",

year = "2017",

month = mar,

day = "1",

doi = "10.1177/1352458516684560",

language = "English (US)",

volume = "23",

pages = "376--377",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "3",

}

TY - JOUR

T1 - Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - Commentary

AU - Calabresi, Peter A.

AU - Van Zijl, Peter C.M.

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: P.A.C. has received grant support from MedImmune, Biogen, Teva and Novartis and has received consulting fees from Biogen and Vertex. P.C.M.V.Z has received grant support from NIH P41EB015909.

PY - 2017/3/1

Y1 - 2017/3/1

UR - http://www.scopus.com/inward/record.url?scp=85014873124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014873124&partnerID=8YFLogxK

U2 - 10.1177/1352458516684560

DO - 10.1177/1352458516684560

M3 - Short survey

C2 - 28260419

AN - SCOPUS:85014873124

SN - 1352-4585

VL - 23

SP - 376

EP - 377

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 3

ER -

Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - Commentary

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this